Winning its second FDA approval this year, Boehringer Ingelheim's oral drug Jascayd is now cleared for use in the U.S. by ...

Columnist Samuel Kirton talks with the Pulmonary Fibrosis Foundation's Amy Hajari Case, MD, about the Accelerate Research ...

GRI-0621, an experimental oral therapy from GRI Bio, boosts lung function in adults with IPF, according to top-line clinical ...

Caring for someone you love is intimate, humbling, and grounding, writes columnist Ann Reynoso, who swapped caregiver roles with her husband.

[vc_row][vc_column][vc_column_text]Pulmonary fibrosis (PF) is a respiratory disease that causes the lung tissue to become thick and stiff. Over time, it turns into scar tissue, which is known as ...

Columnist Sam Kirton has wonderful memories of holiday presents, but the greatest gift he's received came in the form of a lung transplant.

Hello! My name is Kylene Henderson, and I’m excited to be writing a new column for Pulmonary Fibrosis News called “Life Beyond Limits.” In it, I hope to share some of the challenges our family has ...

Building on positive Phase 2 data, Puretech plans to launch a Phase 3 trial to further evaluate its experimental IPF therapy deupirfenidone.

The U.S. Food and Drug Administration (FDA) recently granted orphan drug designation to Calluna Pharma‘s CAL101 as a potential treatment for idiopathic pulmonary fibrosis (IPF). This designation is ...

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...